Pricing Log in Create free account

Kailera Therapeutics, Inc. (KLRA) vs Ultragenyx Pharmaceutical Inc. (RARE)

Kailera Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Kailera Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.6B and $1.5B). Kailera Therapeutics, Inc. has the higher net margin (0.00% vs −71.8%) and the lower return on invested capital (−182.9% vs 0.00%). Across the 10 metrics below, Kailera Therapeutics, Inc. leads on 6 and Ultragenyx Pharmaceutical Inc. on 4.

Valuation

Metric KLRA RARE Biotechnology median
P/E n/m n/m 10.60
P/S n/m 2.17 9.40
P/B 1.63 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1.80 9.02
Earnings yield 661,008,480.09% (33.48%) (32.88%)
Free cash flow yield (19.39%) (28.26%) (23.13%)

Profitability

Metric KLRA RARE Biotechnology median
Gross margin — 82.88% 68.51%
Operating margin 0.00% (63.97%) 0.00%
Net margin 0.00% (71.78%) 0.00%
Free cash flow margin 0.00% (61.23%) 0.00%
Return on equity (85.74%) 285.68% (51.96%)
Return on assets (55.25%) (44.08%) (46.06%)
Return on invested capital (182.92%) 0.00% 0.00%

Growth

Metric KLRA RARE Biotechnology median
Revenue growth (TTM) — 15.75% 6.76%
EPS growth (last fiscal year) — 7.31% 29.88%
Revenue growth, 5-year CAGR — 19.95% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KLRA RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.84 1.40 4.97
Net debt to EBITDA 3.46 1.35 1.01

Dividend

Metric KLRA RARE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KLRA RARE Biotechnology median
Market cap 1.58b 1.54b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack